发明名称 |
THERAPEUTIC BINDING MOLECULES |
摘要 |
A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-lle-lle-His (NYIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys- Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid seuqnce Ser-Gly- Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1', CDR2' and CDR3', CDR1' having the amino acid sequence Arg-Ala-Ser-Gln-Asn-lle-Gly-Thr-Ser-lle-Gln 8RASQNIGTSIQ), CDR', having the amino acid sequence Ser-Ser-Ser-Glu-Ser-lle-Ser (SSSESIS) and CDR3' having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chmieric or humanised antibody, useful as a pharmaceutical.
|
申请公布号 |
CA2437963(A1) |
申请公布日期 |
2002.09.19 |
申请号 |
CA20022437963 |
申请日期 |
2002.02.11 |
申请人 |
NOVARTIS AG |
发明人 |
ASZODI, ANDRAS;SALDANHA, JOSE W.;HALL, BRUCE M.;CARBALLIDO HERRERA, JOSE M.;AVERSA, GREGORIO;KOLBINGER, FRANK |
分类号 |
C12N15/09;A61K39/395;A61P1/00;A61P3/10;A61P5/14;A61P13/12;A61P17/00;A61P17/06;A61P19/02;A61P25/00;A61P29/00;A61P37/00;A61P37/02;A61P37/08;C07H21/00;C07K16/18;C07K16/28;C07K16/46;C12N1/15;C12N1/19;C12N1/21;C12N5/10;C12N15/13;C12P21/08;(IPC1-7):C12N15/13;C12N15/10;C12N15/79 |
主分类号 |
C12N15/09 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|